Methods of treatment using CCR8 antibodies

US12065497B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Sandra BERNDT · Hohen Neuendorf, DE
• Christian Bertling · Wuppertal, DE
• Pascale Buchmann · Leverkusen, DE
• Philipp Ellinger · Düsseldorf, DE
• Katharina Filarsky · Düsseldorf, DE
• Matyas Gorjanacz · Berlin, DE
• Sabine Hoff · Potsdam, DE
• Nikolaus Pawlowski · Cologne, DE
• Helge Roider · Hohen Neuendorf, DE
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Mark Trautwein · Whippany, US
• Ernst Weber · Langenfeld, DE
• Uwe Gritzan · Cologne, DE
• Oliver von Ahsen · Berlin, DE
• Christian Votsmeier · Cologne, DE
• Wiebke Maria Nadler · Langenfeld, DE
• Patrick L. Jones · Danvers, US
• Pedro Paz · Hercules, US
• Su-Yi Tseng · San Francisco, US
• Phaik Lyn Oh · Emeryville, US

Key dates

• Filing date: Apr 22, 2022
• Grant date: Aug 20, 2024
• Expiry date: Apr 22, 2042

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/57492
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.